Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Aytu BioPharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DENVER, CO / ACCESS NEWSWIRE / SEPTEMBER 24, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED MANAGEMENT WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES: MICROCAP RODEO FALL CONFERENCE DATE: THURSDAY, SEPTEMBER 25, 2025 LOCATION: NEW YORK CITY PRESENTATION TIME: 2:00 P.M. EASTERN TIME WEBCAST: HTTPS://WWW.WEBCASTER5.COM/WEBCAST/PAGE/3142/53024 LYTHAM PARTNERS FALL 2025 INVESTOR CONFERENCE DATE: TUESDAY, SEPTEMBER 30, 2025 LOCATION: VIRTUAL PRESENTATION TIME: 2:45 P.M.

AYTU BIOPHARMA TO PRESENT AT UPCOMING SEPTEMBER 2025 CONFERENCES

FULL YEAR FISCAL 2025 NET REVENUE OF $66.4 MILLION FULL YEAR FISCAL 2025 NET LOSS OF $13.6 MILLION FULL YEAR FISCAL 2025 ADJUSTED EBITDA1 OF $9.2 MILLION $31.0 MILLION CASH BALANCE AT JUNE 30, 2025 EXCLUSIVE AGREEMENT IN JUNE 2025 TO COMMERCIALIZE EXXUA (GEPIRONE) EXTENDED-RELEASE TABLETS ("EXXUA") IS EXPECTED TO SERVE AS A MAJOR GROWTH CATALYST; THE COMPANY ANTICIPATES LAUNCHING EXXUA IN THE FOURTH CALENDAR QUARTER OF 2025 AS A CENTERPIECE OF ITS COMMERCIAL EFFORTS AS IT ENTERS THE OVER $22 BILLION UNITED STATES PRESCRIPTION MAJOR DEPRESSIVE DISORDER ("MDD") MARKET WITH WHAT THE COMPANY BELIEVES TO BE A NOVEL FIRST-IN-CLASS ORAL SELECTIVE SEROTONIN 5HT1A RECEPTOR AGONIST FOR ADULTS WITH MDD COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, SEPTEMBER 23, 2025, AT 4:30 P.M. EASTERN TIME DENVER, CO / ACCESS NEWSWIRE / SEPTEMBER 23, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED OPERATIONAL AND FINANCIAL RESULTS FOR THE FISCAL 2025 FULL YEAR AND FOURTH QUARTER.

AYTU BIOPHARMA REPORTS FISCAL 2025 FULL YEAR AND FOURTH QUARTER OPERATIONAL AND FINANCIAL RESULTS AND OUTLINES COMMERCIAL LAUNCH PLANS FOR EXXUA(TM)

DENVER, CO / ACCESS NEWSWIRE / SEPTEMBER 16, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, WILL REPORT ITS OPERATIONAL AND FINANCIAL RESULTS FOR ITS FISCAL 2025 FULL YEAR AND FOURTH QUARTER, AFTER THE MARKET CLOSE ON TUESDAY, SEPTEMBER 23, 2025. THE COMPANY HAS SCHEDULED A CONFERENCE CALL AND WEBCAST THAT SAME DAY, TUESDAY, SEPTEMBER 23, 2025, AT 4:30 P.M.

AYTU BIOPHARMA TO REPORT FISCAL 2025 FULL YEAR AND FOURTH QUARTER OPERATIONAL AND FINANCIAL RESULTS ON SEPTEMBER 23, 2025

HEALTHTECH CFO WITH EXTENSIVE PUBLIC COMPANY EXPERIENCE BUILDING ORGANIZATIONS FOR GROWTH AND VALUE CREATION DEMONSTRATED SUCCESS IN RAISING CAPITAL, DRIVING PROFITABILITY, AND SCALING OPERATIONS TO $500M REVENUE WHILE ENSURING COMPLIANCE AND STRENGTHENING FINANCIAL INTEGRITY BROOMFIELD, CO, SEPTEMBER 3, 2025  PRISM MEDIAWIRE (PRESS RELEASE SERVICE  PRESS RELEASE DISTRIBUTION)  ACLARION, INC.

ACLARION APPOINTS GREG GOULD AS CHIEF FINANCIAL OFFICER

DENVER, CO / ACCESS NEWSWIRE / JUNE 25, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED THE APPOINTMENT OF DR. GERWIN WESTFIELD, PHD AS SENIOR VICE PRESIDENT OF SCIENTIFIC AFFAIRS, EFFECTIVE JUNE 30, 2025. IN HIS ROLE, DR. WESTFIELD WILL OVERSEE THE COMPANY'S MEDICAL AND SCIENTIFIC AFFAIRS STRATEGIES, WITH A PRIMARY FOCUS ON THE UPCOMING COMMERCIAL LAUNCH OF EXXUA (GEPIRONE) EXTENDED-RELEASE TABLETS ("EXXUA"), A NOVEL, BRANDED, UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") APPROVED TREATMENT FOR MAJOR DEPRESSIVE DISORDER ("MDD") IN ADULTS IN THE UNITED STATES.

AYTU BIOPHARMA APPOINTS DR. GERWIN WESTFIELD AS SENIOR VICE PRESIDENT OF SCIENTIFIC AFFAIRS TO SUPPORT COMMERCIALIZATION OF EXXUA(TM)

TERM LOAN MATURITY EXTENDED BY 12 MONTHS TO JUNE 2029 PRINCIPAL BALANCE ON TERM LOAN EXPANDED TO $13.0 MILLION FROM $11.1 MILLION CURRENTLY EXPANDED REVOLVING LINE OF CREDIT FACILITY BY $1.5 MILLION EXPANDED FACILITIES ALLOW FOR ADDED WORKING CAPITAL FLEXIBILITY AS COMMERCIAL LAUNCH OF EXXUA IS ANTICIPATED TO OCCUR IN THE FOURTH CALENDAR QUARTER OF 2025 DENVER, CO / ACCESS NEWSWIRE / JUNE 23, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED IT HAS SUCCESSFULLY EXPANDED AND EXTENDED ITS LENDING AGREEMENT WITH ECLIPSE BUSINESS CAPITAL LLC ("ECLIPSE"), PROVIDING ADDED WORKING CAPITAL FLEXIBILITY AS THE COMPANY PREPARES FOR THE COMMERCIAL LAUNCH OF EXXUA (GEPIRONE) EXTENDED-RELEASE TABLETS ("EXXUA"). GEPIRONE IS A NEW CHEMICAL ENTITY, AND EXXUA IS THE FIRST-IN-CLASS SELECTIVE SEROTONIN 5HT1A RECEPTOR AGONIST APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION ("FDA") FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ("MDD") IN ADULTS.

AYTU BIOPHARMA EXPANDS AND EXTENDS LENDING AGREEMENT WITH ECLIPSE FOLLOWING AGREEMENT TO COMMERCIALIZE FIRST-IN-CLASS ANTIDEPRESSANT EXXUA(TM)

GROSS PROCEEDS FROM OFFERING TOTAL $16.6 MILLION. FINANCING LED BY LONG-TERM, HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS, INCLUDING AYTU'S LARGEST SHAREHOLDERS NANTAHALA CAPITAL MANAGEMENT AND STONEPINE CAPITAL MANAGEMENT, WITH PARTICIPATION FROM AYTU MANAGEMENT AND NEW INSTITUTIONAL SHAREHOLDERS.

AYTU BIOPHARMA ANNOUNCES CLOSING OF UPSIZED AT THE MARKET PUBLIC OFFERING OF COMMON STOCK WITH FULL EXERCISE OF OVERALLOTMENT AND CONFERENCE CALL TO DISCUSS FIRST-IN-CLASS ANTIDEPRESSANT EXXUA(TM) OPPORTUNITY AND COMMERCIALIZATION PLAN

NANTAHALA CAPITAL MANAGEMENT, STONEPINE CAPITAL MANAGEMENT, AYTU MANAGEMENT, AND NEW INSTITUTIONAL SHAREHOLDERS LEAD FINANCING. DENVER, CO / ACCESS NEWSWIRE / JUNE 6, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING NOVEL THERAPEUTICS, TODAY ANNOUNCED THE PRICING OF AN UPSIZED PUBLIC OFFERING OF 9,600,000 SHARES OF COMMON STOCK (OR PREFUNDED WARRANTS IN LIEU THEREOF) AT AN EFFECTIVE PUBLIC OFFERING PRICE OF $1.50.

AYTU BIOPHARMA ANNOUNCES AT THE MARKET PRICING OF $14.4 MILLION UPSIZED PUBLIC OFFERING OF COMMON STOCK

AYTU ENTERS THE OVER $22 BILLION UNITED STATES PRESCRIPTION MAJOR DEPRESSIVE DISORDER ("MDD") MARKET WITH THE FIRST-IN-CLASS ORAL SELECTIVE SEROTONIN 5HT1A RECEPTOR AGONIST FOR ADULTS WITH MDD. EXXUA HAS DEMONSTRATED SIGNIFICANT IMPROVEMENT IN DEPRESSION SYMPTOMS IN CLINICAL TRIALS INVOLVING MORE THAN 5,000 PATIENTS AND, NOTABLY, THE INCIDENCE OF SEXUAL SIDE EFFECTS EXPERIENCED WITH EXXUA WAS COMPARABLE TO PLACEBO.

AYTU BIOPHARMA ANNOUNCES EXCLUSIVE AGREEMENT WITH FABRE-KRAMER PHARMACEUTICALS TO COMMERCIALIZE FIRST-IN-CLASS ANTIDEPRESSANT EXXUA(TM) (GEPIRONE) EXTENDED-RELEASE TABLETS IN THE UNITED STATES

NET INCOME OF $4.0 MILLION, OR $0.65 AND $0.21 NET INCOME PER SHARE BASIC AND DILUTED, RESPECTIVELY ADJUSTED EBITDA1 OF $3.9 MILLION TOTAL NET REVENUE OF $18.5 MILLION UP 32% YEAR-OVER-YEAR COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, MAY 14, 2025, AT 4:30 P.M. EASTERN TIME DENVER, CO / ACCESS NEWSWIRE / MAY 14, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON COMMERCIALIZING NOVEL THERAPEUTICS, TODAY ANNOUNCED OPERATIONAL AND FINANCIAL RESULTS FOR THE FISCAL 2025 THIRD QUARTER.

Aytu BioPharma, Inc.

AYTU

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aytu BioPharma, Inc.

AYTU.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AYTU